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Brief Review
A Translational Approach to Hypertensive Heart Disease
Javier Díez, Edward D. Frohlich
The spectrum of the cardiac complications of arterialhypertension includes heart failure (HF), sudden death,
and cardiac dysrhythmias, as well as the exacerbation of
coincidental diseases (ie, atherosclerosis and chronic renal
disease).1 However, knowledge of the cardiac impact of
chronic elevation of arterial pressure has so evolved that
hypertensive heart disease (HHD) may be thought as those
consequences derived from left ventricular (LV) responses to
fundamental disease mechanisms triggered by mechanical
overload and neurohumoral stimuli.2 For instance, the long-
held views are that LV hypertrophy (LVH), as the result of
cardiomyocyte growth in response to pressure overload,
serves to restore heart muscle economy back to normal and to
preserve LV function.3 However, a number of alterations of
the cardiomyocyte and the noncardiomyocyte components of
the myocardium (including apoptosis, fibrosis, and changes
in the microcirculation) also develop in HHD that lead to
pathological myocardial remodeling not only in the left
ventricle but also the left atrium and right ventricle.2 These
alterations may explain the overall risk of LVH and its
associated cardiac and noncardiac complications in hyperten-
sive patients.4 Although LVH may be detected early and
accurately in hypertensive patients by electrocardiography
and echocardiography, newer cardiac imaging methods and
the monitoring of several circulating biomarkers hold prom-
ise as noninvasive tools for the diagnosis of myocardial
remodeling. Numerous clinical studies have shown that
effective long-term antihypertensive treatment may be asso-
ciated with a decreased LV mass (LVM), which has been
attributed to diminished risk. However, no large study (or
meta-analysis) has demonstrated that diminished risk from
the contemporary reduction of arterial pressure by virtue of
its a priori design. Therefore, because overall risk remains
unacceptably high, especially from HF, new therapeutic
strategies aimed not only to decrease arterial pressure and
LVM but also to repair and even prevent myocardial remod-
eling are necessary. Each of these aspects are reviewed in this
article.
Current Views on the Pathophysiology of HHD
Although hypertrophy provides the response of the cardio-
myocyte to pressure-dependent hemodynamic overload, myo-
cardial remodeling develops as the consequence of a number
of pathological processes, mediated by hormones, growth
factors, cytokines, and other proinflammatory molecules,
acting on the cardiomyocyte and other cellular and noncellu-
lar myocardial components in hypertension (Figure 1).2
Hypertrophic Growth of Cardiomyocytes
Cardiomyocyte hypertrophy leading to LV wall thickening
and LVM increase is the primary mechanism by which the
heart reduces stress on the LV wall imposed by the unrelent-
ing pressure overload (Figure 2).3 However, only a small
proportion of LVM variation is determined by hemodynamic
factors, and other biological influences may also be impor-
tant. Data of integrated genetic and genomic analyses impli-
cate the gene osteoglycin as a key regulator of LVM in
rodents and humans, suggesting that this gene modifies the
hypertrophic response to hemodynamic factors.5 More re-
cently, genetic variation in NPY1R, NPY2R, NPY5R, CPE,
IL15, and SFRP2 (all located in chromosome 4), detected
using linkage analysis in hypertensive siblings, was found to
be associated with LVM in black and white subjects.6
Cardiomyocytic hypertrophy entails stimulation of intra-
cellular signaling cascades that activates gene expression and
promotes protein synthesis, protein stability, or both, with
consequent increases in protein content and the size and
organization of force-generating units (sarcomeres) that, in
turn, results in increased individual cardiomyocyte size.7
Various molecular factors have been identified as being
responsible for the coordinated control of the hypertrophic
genetic program, including the following: natriuretic pep-
tides, adrenergic system, adhesion and cytoskeletal proteins,
interleukin-6 cytokine family, low-molecular weight GT-
Pases (Ras, RhoA, and Rac), mitogen-activated protein ki-
nases, protein kinase C, calcineurin, enzymes involved in
histone deacetylases, and micro-RNAs.8 The long-held views
held that these morphological and genetic changes, in re-
sponse to pressure overload, serve to restore cardiac muscle
economy back to normal and thereby counteract myocardial
dysfunction. However, evidence exists that blunting of car-
diomyocyte hypertrophy and attenuation of the fetal gene
re-expression did not result in dysfunction/failure despite
pressure overload.9 Therefore, one shift in the paradigm is
occurring in the sense that genetic reprogramming associated
with cardiomyocyte hypertrophy is no longer considered an
entirely adaptive process. In fact, detailed analysis of the
genetic changes that accompany cardiomyocyte hypertrophy
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permits the conclusion that they translate into derangements
in energy metabolism, contractile cycle and excitation-
contraction coupling, cytoskeleton and membrane properties,
and autocrine functions, which, in turn, provide the basis for
the cardiomyocyte malfunctioning associated with LVH and
predispose the ventricular chamber to diastolic and/or systolic
dysfunction and HF, as well as to arrhythmias.10
Structural Remodeling of the Myocardium
The conception of remodeling was initially created to de-
scribe the anatomic changes in the left ventricle that occur
after myocardial infarction.11 Today, myocardial remodeling
is used to qualify a variety of changes in the cardiomyocyte
and the volume and composition of the noncardiomyocyte
compartment that alter myocardial structure and function and
occurring in response to myocardial infarction, pressure or
volume overload, cardiomyopathic states, as well as exposure
to infectious or cardiotoxic agents. In particular, hypertensive
myocardial remodeling involves development of increased
rates of cardiomyocyte apoptosis, interstitial and perivascular
fibrosis (Figure 2), and microcirculatory changes.2 Two types
of findings suggest that nonhemodynamic factors critically
determine these lesions in human hypertension.2 First, they
have been identified in both the left and right ventricles,
interventricular septum, and atria of patients with HHD.
Second, the ability of antihypertensive treatment to reverse
these lesions in hypertensive patients is independent of its
antihypertensive efficacy. Thus, myocardial remodeling
could be the consequence of the predominant expression
and/or activity of local and/or circulating molecules that
simulate remodeling mechanisms over molecules that inhibit
remodeling mechanisms (Table 1).2 Of interest, recent clini-
cal and experimental data suggest that specific genetic
factors (ie, variants of the angiotensin type 1 [AT1]
receptor gene),12 local inflammatory (ie, perivascular mac-
rophage accumulation)13 and physicochemical (ie, over-
abundance of reactive oxygen species) factors,14 and en-
vironmental factors (ie, dietary sodium excess)15 may
facilitate the aforementioned imbalance between prore-
modeling and antiremodeling molecules.
Recent observations suggest that apoptosis of cardiomyo-
cytes may contribute to the development of LV dysfunction/
failure of the hypertensive myocardium through 2 different
Hemodynamic
overload
Increased LV
wall tension
Genetic reprogramming and
growth of cardiomyocytes
LV wall
thickening
Systemic and local
humoral disregulation
Unbalance between pro- and
anti-remodeling factors
Altered biophysiology of
cardiac cells and ECM
Myocardial
remodeling
Hypertensive heart disease
Genetic background
Increased blood pressure
Local physico-chemical factors
Environmental factors
Figure 1. Mechanisms involved in the
development of the lesions responsible
for hypertensive heart disease. ECM
indicates extracellular matrix.
Figure 2. Interstitial (bottom left) and perivascular (bottom right)
deposition of collagen fibers (picrosirius red stain, 20) in the
hypertrophied left ventricle (top) of a hypertensive patient.
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pathways (Figure 3). On one hand, an association of in-
creased cardiomyocyte apoptosis with diminished cardio-
myocyte number has been found in HF of hypertensive
patients.16 Apoptosis may serve as one mechanism involved
in the loss of contractile mass and function in HHD. Second,
some mechanisms that are activated during the apoptotic
process may also interfere with the function of viable cardio-
myocytes before death.17 In fact, caspase 3 cleaves cardiac
myofibrillar proteins, resulting in an impaired force/calcium
relationship and myofibrillar ATPase activity. In addition, the
release of cytochrome C from mitochondria during apoptosis
may impair oxidative phosphorylation and ATP production, thus
leading to energetic compromise and functional impairment.
Myocardial fibrosis, secondary to an exaggerated accumu-
lation of collagen type I and type III fibers within the
interstitium and surrounding intramural coronary arteries and
arterioles, is one of the key features of hypertensive myocar-
dial remodeling. Excess myocardial collagen present in LVH
is suggested to result from the combination of several
alterations18: (1) increased procollagen synthesis by fibro-
blasts and phenotypically transformed fibroblast-like cells or
myofibroblasts; (2) increased extracellular conversion of
procollagen into fibril-forming collagen; (3) increased fibril
assembly and cross-linking to form collagen fibers; and (4)
unchanged or decreased collagen fiber degradation by matrix
metalloproteinases. Fibrosis might contribute to the increased
risk of adverse cardiac events in hypertensive patients with
LVH through different pathways (Figure 3). First, a linkage
between fibrosis and LV dysfunction/failure may be estab-
lished.19 Initially, the accumulation of collagen fibers com-
promises the rates of relaxation, diastolic suction, and passive
stiffness, thereby contributing to impaired diastolic function.
Continued accumulation of fibrotic tissue, accompanied by
changes in the spatial orientation of collagen fibers, further
impairs diastolic filling and compromises transduction of
cardiomyocyte contraction into myocardial force develop-
ment, thus impairing systolic performance. Second, impaired
coronary flow reserve (defined as reduced coronary vasodi-
lator response to different stimuli) associated with LVH
might be related to several factors, including perivascular
fibrosis.20 In fact, the amount of perivascular collagen has
been correlated inversely with coronary flow reserve in
hypertensive patients with LVH. Third, interstitial fibrosis
may also contribute to ventricular arrhythmias in hyperten-
sive LVH.21 Thus, hypertensive patients with arrhythmias
exhibited higher values of LVM and myocardial collagen
than patients without arrhythmias, despite the finding that the
ejection fraction and the frequency of coronary vessels with
significant stenosis may be similar in the 2 groups of patients.
Fibrosis, therefore, would induce conduction abnormalities,
such as promoters of local re-entry arrhythmias. Finally,
although the key role of ectopic foci in pulmonary veins as a
trigger of atrial fibrillation has been recognized, structural
remodeling, in particular, atrial fibrosis, has been identified as
the main mechanism for atrial fibrillation persistence.22 This
suggests that atrial fibrosis in hypertensive patients, namely
those with chronic HF, may be a part of more widespread
changes in the myocardial collagen matrix, affecting the left
ventricle and left atrium.
Hypertensive LVH is characterized by different structural
alterations in the small intramyocardial vessels.23 On the one
hand, hyperplasia and/or hypertrophy, as well as altered
alignment of vascular smooth muscle cells, promote en-
croachment of the tunica media into the lumen causing both
an increased medial thickness:lumen ratio and a reduced
maximal cross-sectional area of intramyocardial arteries. On
the other hand, vascular density in LVH (vessel number per
unit area) is relatively decreased. This seems to result from
capillary rarefaction (ie, vessels actually missing or tempo-
rarily nonperfused or “recruited”) and inadequate vascular
growth (ie, impaired angiogenesis) in response to increasing
muscle mass. These microcirculatory alterations, together
with the increased arteriolar tone of hypertension, and endo-
thelial dysfunction also contribute to decreased coronary flow
reserve of hypertensive patients with LVH (Figure 3).24
In summary, histological abnormalities that develop in the
myocardial parenchyma and intramyocardial vasculature of
the hypertensive left ventricle provide structural support for
those alterations of cardiac function, perfusion, and electric
activity that characterize the clinical evolution of HHD.
Revisiting the Clinical Management of HHD
Time has come to revisit current management of HHD simply
focused on detecting LVH and reducing LVM.4 It is now
necessary to develop new approaches aimed at early identi-
fication of hypertensive patients highly vulnerable to the
development of LVH, with more accurate measurement of
LV anatomy and function, noninvasive assessment of those
microscopic changes responsible for myocardial remodeling,
and correction of the molecular and cellular changes of the
myocardium that alter its structure and function (Table 2). In
so doing, the adverse risk associated with HHD should be
reduced more effectively.
Early Detection
In most studies and meta-analyses, the relationship between
changes in office pressure and LVM has been relatively weak
(correlation coefficients: 0.50). Emerging evidence indi-
cates that 24-hour monitoring of pressure may help identify
those hypertensive patients highly predisposed to the devel-
opment of LVH (ie, patients with early morning pressure rise
Table 1. Molecules Involved in Myocardial Remodeling in HHD
Proremodeling molecules
Vasoactive substances (norepinephrine, angiotensin II)
Hormones (thyroid hormone, aldosterone)
Growth factors (transforming growth factor-)
Cytokines (cardiotrophin 1)
Other (reactive oxygen species, endogenous peroxisome
proliferator-activated receptor- ligands)
Antiremodeling molecules
Vasoactive substances (NO, prostacyclin, angiotensin-1-7)
Hormones (glucocorticoids)
Growth factors (insulin-like growth factor 1)
Cytokines (tumor necrosis factor-)
Other (endogenous peroxisome proliferator-activated receptor ligands)
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or with a nondipping profile) and more prone to benefit from
the ability of some antihypertensive drugs to prevent it.25
As mentioned previously, LVM is a highly complex
phenotype influenced by interacting effects of multiple ge-
netic and hemodynamic factors. Genetic variation probably
contributes to interindividual differences in LVM by virtue of
effects on arterial pressure as well as other pathways not
captured by pressure measurement. Identification of genes
that influence LVM may enhance the detection of those
patients requiring early treatment to prevent LVH develop-
ment. In this regard, a meta-analysis of case-control and
association studies has shown that the D allele of the
insertion/deletion polymorphism of the angiotensin-
converting enzyme (ACE) gene behaved as an LVH marker
in untreated hypertensive patients.26 In addition, recent find-
ings suggest that the concomitant presence of the D allele of
the insertion/deletion polymorphism of the ACE gene and the
C allele of the A1166C polymorphism of the AT1 receptor
gene synergistically increased predisposition to diastolic dys-
function/failure in hypertensive patients.27 Of interest, the C
allele of the A1166C polymorphism of the AT1 receptor gene
has been found to be associated with enhanced LV chamber
stiffness in HHD patients.12
Plasma concentration of cardiotrophin 1 (CT-1), a cytokine
belonging to the interleukin 6 cytokine family that induces
cardiomyocyte hypertrophy, is abnormally increased in hy-
pertensive patients, especially those with echocardiographic
LVH.28 Thus, 31% of hypertensive patients without echocar-
diographic LVH already exhibited concentrations of CT-1
abnormally elevated,28 suggesting that circulating levels of
this cytokine increase early during the evolution of arterial
hypertension and, thus, may be useful to identify those
patients predisposed to the development of LVH.
Optimized Diagnosis
New 3D cardiac imaging techniques, including MRI and 3D
echocardiography, can measure LVM and dimensions more
accurately than conventional techniques and may, thus, offer
an advantage.29 Special ultrasound methodologies (ie, speckle
tracking echocardiography aimed to assess LV strains) may
be useful for the detection of myocardial remodeling, espe-
cially fibrosis.30 MRI is another promising technique for
characterizing the myocardial composition, particularly with
the late gadolinium enhancement areas in the myocardium
that probably represent fibrotic regions.31 This methodology
is also rapidly evolving within the field of cardiac molecular
imaging with the introduction of an increasing number of
high-affinity molecular probes imaged at exceptionally high
Cardiomyocyte
apoptosis
Decreased
number
Altered
energetics
Altered Ca2+
metabolism
Altered
relaxation
Increased
stiffness
Perivascular
compression
Decreased
blood supply
Altered
conduction
Impaired
systolic
contraction
Impaired
diastolic
filling
Focal
re-entry
mechanisms
Impaired
coronary
flow reserve
LV dysfunction/failure Arrhythmias         Ischemia
Cardiomyocyte
hypertrophy
Myocardial
fibrosis
Alterations of the
microcirculation
Figure 3. Pathways linking myocardial remodeling with clinical manifestations in hypertensive heart disease.
Table 2. Proposed New Aims for the Clinical Handling of HHD
To identify patients prone to develop LVH
24-h monitoring of blood pressure
Insertion/deletion polymorphism of ACE gene
Circulating cardiotrophin 1
To optimize the diagnosis of LVH
3D echocardiography
MRI
To detect noninvasively myocardial remodeling
Speckle tracking echocardiography
MRI
Nuclear molecular imaging techniques
ELISA of circulating biochemical markers
To provide therapeutic benefit beyond reduction of LVM
Agents (i.e., antihypertensive and nonantihypertensive agents) that repair
myocardial remodeling
Antihypertensive agents that preserve cardiac function, electrical activity,
and intramyocardial perfusion
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spatial resolution. With regard to myocardial remodeling,
molecular imaging is rapidly expanding to involve imaging
and monitoring of apoptosis (ie, using 99mTc-labeled annexin
A5 that binds to apoptotic cardiomyocytes)32 and collagen
synthesis (ie, using 99mTc-labeled peptides that bind to
activated fibroblasts).33
Recent identification of biochemical markers of potential
usefulness for clinical management of cardiac diseases evolv-
ing to HF has been a prolific field. However, for a circulating
molecule can be considered a biochemical marker of hyper-
tensive myocardial remodeling, it must fulfill several crite-
ria.34 Until now, several molecules have been proposed as
biochemical markers of hypertensive myocardial remodeling
that accomplish these criteria. For instance, plasma concen-
tration of CT-1 has been correlated with LVM in untreated
hypertensive patients,28 suggesting that plasma CT-1 may be
a potential marker for the assessment of cardiomyocyte
hypertrophy and LVH in hypertensive patients. In addition,
an association was found between antihypertensive
treatment-induced decrease of plasma CT-1 and reduction of
LVM in patients with LVH,35 suggesting that this cytokine
may be useful to assess the ability of antihypertensive drugs
to reduce cardiomyocyte growth and decrease LVM. On the
other hand, recent data suggest that some biochemical mark-
ers related to myocardial fibrosis (ie, serum carboxy-terminal
propeptide of procollagen type I) or cardiomyocyte apoptosis
(ie, plasma annexin A5) may provide information useful to
assess these aspects of myocardial remodeling in hyperten-
sive patients.34
The common negative aspect of these methodologies is the
high cost that would have to be made available to the large
hypertensive populations internationally. Indeed, to address
their economic impact is a major issue for national health
systems, as is the necessity to make present-day advanced
technology cost-effective. However, the anticipated resultant
reduction in morbidity and mortality with longer productive
lives may tremendously offset those costs.
Effective Reduction of LVM
Antihypertensive drugs have been effective in reducing
LVM. Mosterd et al36 recently analyzed the Framingham
Heart Study data and reported that the increasing use of
effective antihypertensive therapy has decreased the preva-
lence of both hypertension and LVH. Many trials and
meta-analyses have attempted to compare the effects of
different antihypertensive agents on LVM, but flawed study
designs and methodologic problems have limited their utility.
Nevertheless, one meta-analysis including 80 double-blind,
randomized, controlled trials with 146 active treatment arms
and 17 placebo arms showed that, after adjustment for
treatment duration and change in diastolic pressure, there was
a significant difference among medication classes in decreas-
ing LVM.37 The decreased LVM (indexed by body surface
area or LVM index) induced by the different classes was as
follows: AT1 receptor blockerscalcium antagonistsACE
inhibitorsdiuretics-blockers. In paired comparisons,
AT1 receptor blockers, ACE inhibitors, and calcium antago-
nists were more effective at reducing LVM index than
diuretics and -blockers. Remaining questions about these
conclusions exist. Were the clinical status (including pretreat-
ment pressures and the severity of hypertensive disease) and
the accuracy of echocardiographic devices to assess LVM
and dimensions similar to permit these comparisons? Further-
more, with conclusions about reduction of risk with treat-
ment, was this outcome attributable to the decreased LVM or
the result of reduced arterial pressure? Finally, with echocar-
diographically derived LVM, were the effects of the different
pharmacological agents similar on the wall and chamber
dimensions?
Antiremodeling Strategies
In recent trials in hypertension, development of HF was
comparable with stroke.38 Thus, physicians should be aware
that HF still represents a frequent and deleterious conse-
quence of hypertension. Also, recent Framingham Heart
Study data suggest that causal classification may help to
reduce syndromic heterogeneity, providing a disease patho-
genesis–oriented approach to patients with HF (ie, hyperten-
sion facilitates HF with preserved ejection fraction).39 These
points underscore the necessity of addressing a new paradigm
concerning HHD, its risk, and diagnostic and therapeutic
approaches. Appropriate strategies to effectively fight the
development of HF during its asymptomatic stages when
early structural and functional cardiac abnormalities are
identified should be applied to hypertensive patients with a
high-risk profile (ie, patients with HHD). In this conceptual
framework, beyond controlling pressure and reducing LVM,
it is necessary, indeed essential, to pay attention to strategies
focused on repairing myocardial remodeling.
Cumulating experimental evidence suggest that sodium
loading exacerbates target organ damage associated with
long-standing hypertension. In particular, sodium loading not
only further increased arterial pressure and LVM in sponta-
neously hypertensive rats but also impaired LV and right
ventricular diastolic functions and coronary flow reserve
associated with enhanced interstitial and perivascular fibro-
sis.15 The observation that AT1 receptor blockade with
low-dose candesartan failed to reduce the salt-induced rise in
pressure but significantly attenuated LVM, myocardial fibro-
sis, and the development of LV diastolic dysfunction in
spontaneously hypertensive rats40 suggests that angiotensin II
contributed to the pressure-independent remodeling effect of
salt excess on the hypertensive myocardium. Therefore, salt
restriction, shown previously to lower pressure and prevent
hypertension, may also prevent myocardial remodeling and
other target organ damage associated with hypertension. This
possibility is supported in part by recent findings from the
Trials of Hypertension Prevention Study showing that reduc-
tion in dietary sodium intake reduced long-term risk of
cardiovascular complications.41
Available experimental data suggest that the goal of
repairing myocardial remodeling is achievable in HHD using
specific antihypertensive agents (Table 3).42 Clinical studies
provide important support to this possibility. Brilla et al43
reported that, in patients with HHD, ACE inhibition regressed
myocardial fibrosis, irrespective of LVM reduction, and it
was accompanied by improved LV diastolic function. These
effects were not observed in the patients treated with hydro-
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chlorothiazide despite similar pressure control. Long-term
ACE inhibitor therapy has also promoted structural repair of
coronary arterioles that was mainly characterized by the
regression of periarteriolar fibrosis and marked improvement
in coronary flow reserve in patients with HHD.44 In addition,
despite similar antihypertensive and antihypertrophic effi-
cacy, an AT1 receptor blocker, but not a calcium antagonist,
reduced histologically proven cardiomyocyte apoptosis45 and
myocardial fibrosis46 in patients with HHD. Reduction of
myocardial fibrosis by the AT1 blocker was associated with
decreased LV chamber stiffness and the improvement of
diastolic filling in hypertensive patients.47 Recently, treat-
ment with the loop diuretic torsemide, but not furosemide,
was associated with a reduction of myocardial fibrosis and a
trend toward improved LV function in patients with hyper-
tensive HF.48 Of interest, the diuretic and hemodynamic
effects of the 2 compounds were similar. These data bring to
mind 2 questions. On the one hand, the long-standing
question remains as to the similarity of all pharmacological
agents that are classified under the “label” of a same drug
class. On the other hand, there is the question regarding the
necessity of using drugs with a potential antifibrotic capacity
to both prevent diastolic dysfunction that precedes HF in
hypertensive patients and to treat hypertensive patients with
HF and preserved ejection fraction.49
Current therapy of myocardial remodeling is presently
based on targeting mechanical and humoral causative mech-
anisms. However, multiple and redundant signaling systems
are involved in remodeling. Thus, novel therapeutic strategies
may be necessary to reverse or even prevent myocardial
remodeling. Recent insights from experimental studies have
provided new targets for interventions.50–53 The first insight is
to act on those genetic mechanisms that intrinsically regulate
the hypertrophic responses of the cardiomyocyte (ie, modu-
lating activated osteoglycin-related pathways) or the profi-
brotic response of the fibroblast/myofibroblast (ie, inhibiting
micro-RNA 29 or stimulating micro-RNAs 21 and 208). The
second is to block the detrimental intracellular mechanisms
activated by biomechanical stress on cardiomyocytes (ie,
inhibiting intracellular renin activation and angiotensin II
generation, superoxide anion generation by NADPH oxidase,
and overstimulation of kinases, such as Rho-kinase, and
phosphatases, such as calcineurin). Third is to prevent inhi-
bition of negative signaling modulators and negative inter-
acting proteins that are repressed by biomechanical stress in
the cardiomyocyte (ie, increasing the availability and actions
of cyclic GMP). Fourth is to preserve functioning cardiomyo-
cytes (ie, through inhibition of apoptosis via poly [ADP-
ribose] polymerase inhibition and/or preservation of cell
survival mechanisms via insulin-like growth factor 1 activa-
tion) or to regenerate lost cardiomyocytes (ie, using stem cell
therapy). Fifth is to restore normal turnover of the collagen
network at the fibroblast and myofibroblast level (ie, modu-
lating the synthesis and secretion of procollagen precursors,
as well as of those enzymes controlling the extracellular
processes of fibril and fiber formation, as well as degrada-
tion). Last is to stimulate the angiogenic activity of endothe-
lial cells (ie, stimulating phosphatidylinositol 3-kinase-Akt-
NO–mediated mechanisms).
Concluding Remarks
Classical conceptualization has considered HHD as the adap-
tive hypertrophy of LV wall to increased pressure. Recent
findings in hypertensive animals and patients now challenge
this paradigm by demonstrating that HHD also results from
pathological structural remodeling of the myocardium in
response to a mosaic of hemodynamic and nonhemodynamic
factors altered in hypertension. We anticipate that this ex-
panded view will benefit from the application of integrated
“omic” methodologies aimed to reveal critical genes, path-
ways, and networks for LV growth and myocardial remodel-
ing. The potential clinical relevance of this shift in paradigm
is strengthened by the fact that it entails a new approach to
HHD in terms of a more precise diagnosis and more demand-
ing treatment. In addition, available information sets the stage
for large and long-term clinical trials aimed at determining
whether the diagnosis and reversal of myocardial remodeling
in HHD are associated with greater benefit on the patient’s
cardiac function and prognosis than simply detecting and
regressing LVH. This novel view of HHD may have tremen-
dous epidemiological importance. In fact, the possibility that
hypertensive patients predisposed to develop HHD may be
detected before the appearance of clinical detectable LVH
opens a new way to prevent cardiac complications associated
with hypertension and its cardiac impact, especially HF.
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